In a clinical study (NCT01203943), a JNK inhibitor (CC-930) effectively attenuated airway remodeling, reduced the production of pulmonary fibrosis markers, and improved lung function (van der Velden et al., 2016). This evidence concerns the gene MAPK8 and pulmonary fibrosis.